An innovative engineering firm specializing in industrial equipment for the food manufacturing sector is set to expand its footprint across the UK and Europe after receiving full patent approval for its breakthrough emissions control product.
FEG Global, headquartered in Washington, UK, has developed the LGC Scrubber, a patented system designed to revolutionize odour and oil mist management in food production facilities. The technology is aimed at companies involved in high-temperature frying, cooking, coating, or seasoning—common in seafood, meat, poultry, ready meals, and snack food manufacturing.
The LGC Scrubber features a dual-function system that combines a particulate wet scrubber and a gas scrubber. This allows it to effectively capture and eliminate both oil mist and volatile odour compounds from industrial food processing operations. Its modular design makes it adaptable for integration into existing factory layouts, providing a practical and scalable solution for food manufacturers.
One of the standout benefits of the LGC Scrubber is its potential contribution to the circular economy. The system allows for the collection and possible repurposing of waste emissions—such as oil particles—as biofuel, opening up additional revenue streams for users.
Following the patent approval, FEG Global plans to ramp up sales and installations of the LGC Scrubber across European markets. The company already operates regional offices in the Midlands, Glasgow, and Belgium, positioning it strategically for cross-border growth.
Chris Williams, Managing Director of FEG Global, emphasized the broader impact of the innovation:
The LGC Scrubber is not just a technical achievement; it’s a practical, market-ready solution that addresses critical environmental and operational challenges for food manufacturers. As housing developments increasingly encroach on industrial zones, managing odours and emissions isn’t just good practice—it’s essential for regulatory compliance and community relations.”
The system has already been successfully implemented by Whitby Seafoods, one of the UK’s largest seafood processors known for its iconic Whitby Scampi. The company, which processes over 3,000 tonnes of scampi annually, required a reliable system to manage odours in its high-temperature production environment.
Chris Dickinson, Head of Engineering at Whitby Seafoods, praised the partnership:
“We needed a solution that met our environmental standards while integrating seamlessly into our operational setup. FEG Global delivered exactly that. The LGC Scrubber installation has allowed us to maintain high production volumes while ensuring we continue to meet our environmental responsibilities as a local employer and good neighbour.”
As regulatory pressures mount and community awareness grows around industrial emissions, FEG Global’s LGC Scrubber is poised to become a critical solution for food manufacturers seeking to future-proof their operations while maintaining environmental stewardship.
AI
Unilin Technologies Secures European Patent for Groundbreaking Osiris Wood Recycling Technology
Unilin Technologies, the intellectual property division of Unilin, has been awarded European patent EP 4114629 for its pioneering Osiris recycling technology. This patent marks a significant milestone in the company’s mission to foster circular practices in the wood industry and reflects Unilin’s ongoing investment in sustainable innovation.
The patented Osiris system represents the first industrial-scale technology capable of recycling fiberboards—a long-standing challenge in the wood-based panel industry. Historically, the composite structure of fiberboards, which combines wood fibers with adhesives and resins, made them difficult to disassemble and therefore unfit for effective recycling. As a result, these boards typically ended up in landfills or were incinerated, contributing to environmental degradation.
With Osiris, Unilin has developed a scalable and practical solution to this issue. The technology enables the efficient separation of wood fibers from waste fiberboards, which can then be reintegrated with virgin wood to manufacture new fiberboards. This process not only reduces waste but also conserves natural resources by decreasing reliance on fresh wood material.
The Osiris technology is exclusively offered for licensing by Unilin Technologies in partnership with Dieffenbacher, a leading provider of wood-based panel production systems.
“We are proud to receive this patent, which underscores the innovation behind Osiris and the impact it can have on the sustainability of the fiberboard industry,” said a spokesperson from Unilin Technologies. “Our goal is to create real-world solutions that allow manufacturers to reduce their environmental footprint while maintaining high production standards.”
The granting of this European patent further strengthens Unilin’s intellectual property portfolio and opens the door for wider adoption of circular technologies across the board manufacturing sector. With global attention increasingly focused on sustainable production methods, Osiris offers a viable path forward for companies seeking to align with environmental targets without compromising efficiency or quality.
The patented Osiris system represents the first industrial-scale technology capable of recycling fiberboards—a long-standing challenge in the wood-based panel industry. Historically, the composite structure of fiberboards, which combines wood fibers with adhesives and resins, made them difficult to disassemble and therefore unfit for effective recycling. As a result, these boards typically ended up in landfills or were incinerated, contributing to environmental degradation.
With Osiris, Unilin has developed a scalable and practical solution to this issue. The technology enables the efficient separation of wood fibers from waste fiberboards, which can then be reintegrated with virgin wood to manufacture new fiberboards. This process not only reduces waste but also conserves natural resources by decreasing reliance on fresh wood material.
The Osiris technology is exclusively offered for licensing by Unilin Technologies in partnership with Dieffenbacher, a leading provider of wood-based panel production systems.
“We are proud to receive this patent, which underscores the innovation behind Osiris and the impact it can have on the sustainability of the fiberboard industry,” said a spokesperson from Unilin Technologies. “Our goal is to create real-world solutions that allow manufacturers to reduce their environmental footprint while maintaining high production standards.”
The granting of this European patent further strengthens Unilin’s intellectual property portfolio and opens the door for wider adoption of circular technologies across the board manufacturing sector. With global attention increasingly focused on sustainable production methods, Osiris offers a viable path forward for companies seeking to align with environmental targets without compromising efficiency or quality.
Heron Therapeutics Reaches Patent Settlement with Mylan Over Cancer-Related Drugs
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biopharmaceutical firm valued at approximately $324 million, has resolved ongoing patent litigation with Mylan Pharmaceuticals, Inc., a Viatris Inc. subsidiary.
Under the terms of the agreement, Heron has granted Mylan the right to begin selling generic alternatives to both drugs starting June 1, 2032. This resolution ends two separate legal proceedings filed in the U.S. District Court for the District of Delaware, which were initiated in September 2023 and January 2024 after Mylan sought FDA approval for generics ahead of the drugs’ patent expirations in 2035. As part of the agreement, both companies will ask the court to dismiss the lawsuits.
CINVANTI® and APONVIE® are formulations of the active ingredient aprepitant, used to prevent chemotherapy-induced nausea and vomiting. The deal allows for the possibility of an earlier launch of Mylan’s generics under standard conditions, although the formal market entry date remains set for 2032.
Heron, known for its focus on acute care and oncology-related treatments, continues to show signs of financial health and strategic growth. InvestingPro data shows a solid current ratio of 2.29, indicating strong short-term liquidity. The company has also reported a 13.57% increase in revenue over the last 12 months.
The patent settlement comes on the heels of a strong fourth quarter for Heron. The company reported adjusted earnings of $0.02 per share, outperforming analysts’ expectations of a $0.03 loss. Quarterly revenue reached $40.78 million—above the $37.3 million forecast—and reflected a 19.1% increase year-over-year. A significant contributor was ZYNRELEF, Heron’s pain management therapy, which brought in $8.5 million in Q4, up nearly 49% from the same period last year.
For the full year 2024, Heron posted total revenue of $144.2 million, a 13.6% increase compared to 2023. Looking ahead, the company projects 2025 revenues between $153 million and $163 million, in line with analyst expectations. Additionally, Heron estimates adjusted EBITDA between $0 and $8 million for the year.
In December 2024, the company expanded the label indications for ZYNRELEF and introduced a new vial access needle, further enhancing its product offerings. Heron closed the year with $59.3 million in cash and short-term investments, reinforcing its financial stability as it continues to grow its commercial footprint.
Under the terms of the agreement, Heron has granted Mylan the right to begin selling generic alternatives to both drugs starting June 1, 2032. This resolution ends two separate legal proceedings filed in the U.S. District Court for the District of Delaware, which were initiated in September 2023 and January 2024 after Mylan sought FDA approval for generics ahead of the drugs’ patent expirations in 2035. As part of the agreement, both companies will ask the court to dismiss the lawsuits.
CINVANTI® and APONVIE® are formulations of the active ingredient aprepitant, used to prevent chemotherapy-induced nausea and vomiting. The deal allows for the possibility of an earlier launch of Mylan’s generics under standard conditions, although the formal market entry date remains set for 2032.
Heron, known for its focus on acute care and oncology-related treatments, continues to show signs of financial health and strategic growth. InvestingPro data shows a solid current ratio of 2.29, indicating strong short-term liquidity. The company has also reported a 13.57% increase in revenue over the last 12 months.
The patent settlement comes on the heels of a strong fourth quarter for Heron. The company reported adjusted earnings of $0.02 per share, outperforming analysts’ expectations of a $0.03 loss. Quarterly revenue reached $40.78 million—above the $37.3 million forecast—and reflected a 19.1% increase year-over-year. A significant contributor was ZYNRELEF, Heron’s pain management therapy, which brought in $8.5 million in Q4, up nearly 49% from the same period last year.
For the full year 2024, Heron posted total revenue of $144.2 million, a 13.6% increase compared to 2023. Looking ahead, the company projects 2025 revenues between $153 million and $163 million, in line with analyst expectations. Additionally, Heron estimates adjusted EBITDA between $0 and $8 million for the year.
In December 2024, the company expanded the label indications for ZYNRELEF and introduced a new vial access needle, further enhancing its product offerings. Heron closed the year with $59.3 million in cash and short-term investments, reinforcing its financial stability as it continues to grow its commercial footprint.
Baidu Explores AI Technology to Decode Animal Communication
Ever wondered what your cat’s meows actually mean? Chinese tech giant Baidu is aiming to bridge the communication gap between humans and animals with the help of artificial intelligence.
The proposed technology would combine data on animal vocalizations, behavioral cues, and bodily responses, then process this information using AI to identify emotional states. These emotional indicators would subsequently be translated into semantic content understandable by humans.
Baidu’s patent describes the project as a step toward “deeper emotional communication and understanding between animals and humans,” potentially making cross-species interaction more accurate and efficient. While the concept has captured public interest, the company has clarified that the system remains in the research phase.
This effort is part of Baidu’s broader strategy to lead in AI innovation. The company has been investing heavily in artificial intelligence since the rise of OpenAI’s ChatGPT in 2022. Baidu recently introduced its advanced AI model, Ernie 4.5 Turbo, claiming it performs at the top tier across industry benchmarks. Despite these advancements, Baidu’s chatbot offerings have faced challenges in gaining widespread user adoption due to intense competition.
Globally, Baidu is not alone in its quest to decode animal language. Projects like CETI (Cetacean Translation Initiative), launched in 2020, are working to interpret the complex communication of sperm whales using AI and statistical models. Meanwhile, the Earth Species Project, founded in 2017 and backed by tech figures like LinkedIn co-founder Reid Hoffman, is also using artificial intelligence to analyze animal communication across various species.
While the dream of talking to animals like a real-life Dr. Dolittle remains a long-term goal, advances like Baidu’s patent hint at a future where technology could help us better understand the emotional and communicative world of animals.
The proposed technology would combine data on animal vocalizations, behavioral cues, and bodily responses, then process this information using AI to identify emotional states. These emotional indicators would subsequently be translated into semantic content understandable by humans.
Baidu’s patent describes the project as a step toward “deeper emotional communication and understanding between animals and humans,” potentially making cross-species interaction more accurate and efficient. While the concept has captured public interest, the company has clarified that the system remains in the research phase.
This effort is part of Baidu’s broader strategy to lead in AI innovation. The company has been investing heavily in artificial intelligence since the rise of OpenAI’s ChatGPT in 2022. Baidu recently introduced its advanced AI model, Ernie 4.5 Turbo, claiming it performs at the top tier across industry benchmarks. Despite these advancements, Baidu’s chatbot offerings have faced challenges in gaining widespread user adoption due to intense competition.
Globally, Baidu is not alone in its quest to decode animal language. Projects like CETI (Cetacean Translation Initiative), launched in 2020, are working to interpret the complex communication of sperm whales using AI and statistical models. Meanwhile, the Earth Species Project, founded in 2017 and backed by tech figures like LinkedIn co-founder Reid Hoffman, is also using artificial intelligence to analyze animal communication across various species.
While the dream of talking to animals like a real-life Dr. Dolittle remains a long-term goal, advances like Baidu’s patent hint at a future where technology could help us better understand the emotional and communicative world of animals.
Flux Power Holdings Secures Patent for Groundbreaking AI-Powered Battery Cycle Life Maximization Algorithm
Flux Power Holdings, Inc. (NASDAQ: FLUX), a pioneering developer of advanced lithium-ion energy storage solutions, today announced that it has been granted a patent for its innovative Intelligent Battery Cycle Life Maximization Algorithm. This proprietary AI-driven technology is designed to optimize the performance and longevity of its battery systems by leveraging machine learning to adapt to real-world usage. With this breakthrough, Flux Power is positioning itself as a leader not only in energy storage but also in the development of software-driven electrification solutions for commercial and industrial sectors.
A Leap Forward in Battery Management
Flux Power’s latest patent reflects a major step forward in the evolution of battery management technologies. The Intelligent Battery Cycle Life Maximization Algorithm uses machine learning to continuously monitor and adjust the charging behavior of lithium-ion battery packs based on real-time usage data. By dynamically optimizing the maximum charge value for each battery pack depending on its actual field usage, the algorithm extends the cycle life of the batteries, improving both efficiency and operational performance.
Paulus Geantil, Chief Technology Officer (CTO) of Flux Power, explained the significance of the development:
“This algorithm uses real-time machine learning to tune battery cycling behavior based on actual usage patterns in the field, significantly extending system life and efficiency,” he said. “We’ve moved beyond conventional battery management systems. This algorithm not only optimizes the performance of each battery pack but learns and evolves with its application over time to deliver superior and sustainable performance.”
The new algorithm is a pivotal component of Flux Power’s broader strategy to evolve from being a battery manufacturer to a technology-driven energy solutions provider. This move aligns with the company’s goal of building smart, connected, and autonomous energy ecosystems that extend far beyond the simple manufacture of energy storage hardware.
Shaping the Future of Energy with AI
As the demand for sustainable and efficient energy solutions grows, Flux Power is looking to meet this demand by incorporating artificial intelligence (AI) and machine learning into its core products. The company’s CEO, Krishna Vanka, highlighted the shift towards AI-driven solutions, emphasizing the added value customers will gain from the new technology:
As the electrification of commercial and industrial equipment continues to accelerate, Flux Power is well-poised to capitalize on the shift towards battery-powered solutions that provide longer life cycles, improved operational efficiency, and reduced environmental impact. With the addition of this cutting-edge AI technology, Flux Power is positioning itself as a key player in the energy transformation landscape.
About Flux Power Holdings, Inc.
Flux Power Holdings, Inc. These sectors include material handling, airport ground support equipment (GSE), and stationary energy storage. Flux Power’s products provide a high-performance, environmentally friendly, and cost-effective alternative to traditional energy solutions, such as lead-acid and propane-based systems. By focusing on battery management systems (BMS), telemetry, and AI-driven innovations, Flux Power continues to expand its footprint in the energy storage industry.
Forward-Looking Statements
This release contains forward-looking statements that involve estimates, assumptions, risks, and other uncertainties, which may cause actual results to differ materially from those anticipated. These statements are not guarantees of future results, and actual results could vary based on a range of factors including market conditions, customer acceptance, product development, and other business risks. Investors are encouraged to review the risk factors outlined in Flux Power’s filings with the Securities and Exchange Commission (SEC) for further details.
A Leap Forward in Battery Management
Flux Power’s latest patent reflects a major step forward in the evolution of battery management technologies. The Intelligent Battery Cycle Life Maximization Algorithm uses machine learning to continuously monitor and adjust the charging behavior of lithium-ion battery packs based on real-time usage data. By dynamically optimizing the maximum charge value for each battery pack depending on its actual field usage, the algorithm extends the cycle life of the batteries, improving both efficiency and operational performance.
Paulus Geantil, Chief Technology Officer (CTO) of Flux Power, explained the significance of the development:
“This algorithm uses real-time machine learning to tune battery cycling behavior based on actual usage patterns in the field, significantly extending system life and efficiency,” he said. “We’ve moved beyond conventional battery management systems. This algorithm not only optimizes the performance of each battery pack but learns and evolves with its application over time to deliver superior and sustainable performance.”
The new algorithm is a pivotal component of Flux Power’s broader strategy to evolve from being a battery manufacturer to a technology-driven energy solutions provider. This move aligns with the company’s goal of building smart, connected, and autonomous energy ecosystems that extend far beyond the simple manufacture of energy storage hardware.
Shaping the Future of Energy with AI
As the demand for sustainable and efficient energy solutions grows, Flux Power is looking to meet this demand by incorporating artificial intelligence (AI) and machine learning into its core products. The company’s CEO, Krishna Vanka, highlighted the shift towards AI-driven solutions, emphasizing the added value customers will gain from the new technology:
As the electrification of commercial and industrial equipment continues to accelerate, Flux Power is well-poised to capitalize on the shift towards battery-powered solutions that provide longer life cycles, improved operational efficiency, and reduced environmental impact. With the addition of this cutting-edge AI technology, Flux Power is positioning itself as a key player in the energy transformation landscape.
About Flux Power Holdings, Inc.
Flux Power Holdings, Inc. These sectors include material handling, airport ground support equipment (GSE), and stationary energy storage. Flux Power’s products provide a high-performance, environmentally friendly, and cost-effective alternative to traditional energy solutions, such as lead-acid and propane-based systems. By focusing on battery management systems (BMS), telemetry, and AI-driven innovations, Flux Power continues to expand its footprint in the energy storage industry.
Forward-Looking Statements
This release contains forward-looking statements that involve estimates, assumptions, risks, and other uncertainties, which may cause actual results to differ materially from those anticipated. These statements are not guarantees of future results, and actual results could vary based on a range of factors including market conditions, customer acceptance, product development, and other business risks. Investors are encouraged to review the risk factors outlined in Flux Power’s filings with the Securities and Exchange Commission (SEC) for further details.
U.S. Court of Appeals for the Federal Circuit Invalidates Patents Over Functional Claim Language in “Payment Handler” Case: Implications for AI Patents
In a precedential decision issued by the U.S. Court of Appeals for the Federal Circuit in February 2025, the court affirmed a district court ruling that the term “payment handler” in a patent claim was a “nonce” term—a placeholder for functional language. This ruling invoked 35 U.S.C. § 112, sixth paragraph, governing means-plus-function claiming, leading to the invalidation of the associated patents. The decision raises crucial questions about the drafting of patent claims in industries like artificial intelligence (AI), where functional language is often used to describe complex systems.
The Case: Payment Handler as Functional Language
The case, involving a dispute over software patents related to payment processing technologies, centered on the term “payment handler.” The court examined whether this term invoked means-plus-function claiming under § 112 ¶6, which applies when a claim term is expressed in purely functional terms, without reciting sufficient structural detail. Under this provision, if a claim lacks structural detail, it is considered indefinite unless the specification provides enough supporting structure or an algorithm corresponding to the claimed function.
The Federal Circuit began by discussing whether the term “payment handler” overcame the presumption against invoking means-plus-function claiming. The court ruled that the term indeed lacked sufficient structural specificity, as it only described the function of handling payments without specifying how this was achieved. The court likened the term “payment handler” to “module”, which has previously been considered a nonce term in patent law, representing a vague description of a software or hardware component that performs a specified function.
Why “Payment Handler” Was Deemed Indefinite
The court rejected several arguments put forth by the patent holder. For one, the plaintiff argued that terms like “operable to,” “configured to,” and “that” used in the claim language conferred sufficient structure to avoid means-plus-function treatment. The Federal Circuit noted that while these terms are often used in structural contexts, they do not automatically prevent means-plus-function claiming. Citing the case Rain Computing, Inc. v. Samsung Electronics America, the court pointed out that the applicability of § 112 ¶6 depends on the specific context and nature of the claims.
The court also addressed the argument that the “payment handler” terms were part of a recognized class of software structures like “code” or “applications,” which the court in Dyfan, LLC v. Target Corp. found to be sufficiently structural. However, the Federal Circuit emphasized that, unlike “code” or “application,” the term “payment handler” had no established meaning within the software development community. The patent holder had failed to provide expert testimony or concrete examples showing how the term conveyed structure.
Additionally, the court rejected the argument that the surrounding claim language—such as defining inputs, outputs, and operation of the payment handler—provided enough detail to make the term structural. The claim did not explain how the payment handler functioned, nor did it outline the specific “rules” or algorithm that would govern its operation. The Federal Circuit noted that the specification of the patent simply repeated the claim language without offering any substantial details about the underlying structure of the payment handler.
In essence, the court concluded that the term “payment handler” was functionally indefinite and did not include the necessary structural disclosure to satisfy § 112 ¶6. As a result, the court invalidated the patent claims that relied on this vague term.
Implications for AI Patent Applications
Although this decision did not directly address artificial intelligence (AI), it offers significant insights for AI-related patent drafting, where functional terms are often used to describe complex technologies. AI inventions, particularly those involving machine learning models, neural networks, and other advanced algorithms, may face similar challenges when their claims rely heavily on functional descriptions.
In AI patents, terms like “classifier,” “predictive model,” or “neural network” are often used to describe the operations of a system without fully detailing the underlying algorithm or architecture. While these terms may be widely accepted in the field, patent drafters must be cautious when they lack sufficient structural disclosure in the specification.
Provide Detailed Structural Descriptions: Instead of relying on broad, functional terms like “classifier” or “model,” drafters should disclose as much structural detail as possible, including algorithms and specific AI techniques used. For example, terms like “feed-forward neural network,” “convolutional neural network,” or “generative pre-trained transformer” provide concrete examples of structures and algorithms that could support the claims and avoid indefiniteness challenges.
Avoid Ambiguous Terminology: Terms like “handler” or “module,” which are commonly used as placeholders for functional components, should be avoided or supplemented with detailed explanations of their structure and operation. If a term like “payment handler” is essential, ensure the patent specification includes an in-depth description of the specific software or hardware involved and how it performs its function.
Use Recognized AI Terms for Structure: Where possible, use terms that are already well understood to connote structure in the AI field. For instance, the term “model” could be more structural in the AI context than terms like “classifier,” especially when it is described with reference to specific AI architectures and algorithms.
Include Dependent Claims for Clarity: Dependent claims can be used to provide more specific details on the structure of AI systems, such as the type of neural network or the algorithm being used.
Don’t Rely Solely on Claim Language: As the court emphasized, merely parroting the claim language in the specification is not enough. It’s crucial to explain the structural components in detail, particularly for AI inventions that involve complex algorithms and system architectures.
Conclusion: The Need for Clarity in AI Patents
The Federal Circuit’s decision underscores the importance of clarity and specificity in patent claims, particularly in fields like software and AI, where functional terms are commonly used. Patent applicants must ensure that functional language is supported by concrete structural details to avoid claims being deemed indefinite under § 112 ¶6. By providing comprehensive descriptions of the structure and algorithms underlying their inventions, AI patent drafters can strengthen their patent applications and reduce the risk of invalidation due to indefiniteness.
As AI technologies continue to evolve, patent law will need to adapt, and the case serves as a timely reminder that functional claims must be backed by sufficient structure to withstand legal scrutiny.
The Case: Payment Handler as Functional Language
The case, involving a dispute over software patents related to payment processing technologies, centered on the term “payment handler.” The court examined whether this term invoked means-plus-function claiming under § 112 ¶6, which applies when a claim term is expressed in purely functional terms, without reciting sufficient structural detail. Under this provision, if a claim lacks structural detail, it is considered indefinite unless the specification provides enough supporting structure or an algorithm corresponding to the claimed function.
The Federal Circuit began by discussing whether the term “payment handler” overcame the presumption against invoking means-plus-function claiming. The court ruled that the term indeed lacked sufficient structural specificity, as it only described the function of handling payments without specifying how this was achieved. The court likened the term “payment handler” to “module”, which has previously been considered a nonce term in patent law, representing a vague description of a software or hardware component that performs a specified function.
Why “Payment Handler” Was Deemed Indefinite
The court rejected several arguments put forth by the patent holder. For one, the plaintiff argued that terms like “operable to,” “configured to,” and “that” used in the claim language conferred sufficient structure to avoid means-plus-function treatment. The Federal Circuit noted that while these terms are often used in structural contexts, they do not automatically prevent means-plus-function claiming. Citing the case Rain Computing, Inc. v. Samsung Electronics America, the court pointed out that the applicability of § 112 ¶6 depends on the specific context and nature of the claims.
The court also addressed the argument that the “payment handler” terms were part of a recognized class of software structures like “code” or “applications,” which the court in Dyfan, LLC v. Target Corp. found to be sufficiently structural. However, the Federal Circuit emphasized that, unlike “code” or “application,” the term “payment handler” had no established meaning within the software development community. The patent holder had failed to provide expert testimony or concrete examples showing how the term conveyed structure.
Additionally, the court rejected the argument that the surrounding claim language—such as defining inputs, outputs, and operation of the payment handler—provided enough detail to make the term structural. The claim did not explain how the payment handler functioned, nor did it outline the specific “rules” or algorithm that would govern its operation. The Federal Circuit noted that the specification of the patent simply repeated the claim language without offering any substantial details about the underlying structure of the payment handler.
In essence, the court concluded that the term “payment handler” was functionally indefinite and did not include the necessary structural disclosure to satisfy § 112 ¶6. As a result, the court invalidated the patent claims that relied on this vague term.
Implications for AI Patent Applications
Although this decision did not directly address artificial intelligence (AI), it offers significant insights for AI-related patent drafting, where functional terms are often used to describe complex technologies. AI inventions, particularly those involving machine learning models, neural networks, and other advanced algorithms, may face similar challenges when their claims rely heavily on functional descriptions.
In AI patents, terms like “classifier,” “predictive model,” or “neural network” are often used to describe the operations of a system without fully detailing the underlying algorithm or architecture. While these terms may be widely accepted in the field, patent drafters must be cautious when they lack sufficient structural disclosure in the specification.
Provide Detailed Structural Descriptions: Instead of relying on broad, functional terms like “classifier” or “model,” drafters should disclose as much structural detail as possible, including algorithms and specific AI techniques used. For example, terms like “feed-forward neural network,” “convolutional neural network,” or “generative pre-trained transformer” provide concrete examples of structures and algorithms that could support the claims and avoid indefiniteness challenges.
Avoid Ambiguous Terminology: Terms like “handler” or “module,” which are commonly used as placeholders for functional components, should be avoided or supplemented with detailed explanations of their structure and operation. If a term like “payment handler” is essential, ensure the patent specification includes an in-depth description of the specific software or hardware involved and how it performs its function.
Use Recognized AI Terms for Structure: Where possible, use terms that are already well understood to connote structure in the AI field. For instance, the term “model” could be more structural in the AI context than terms like “classifier,” especially when it is described with reference to specific AI architectures and algorithms.
Include Dependent Claims for Clarity: Dependent claims can be used to provide more specific details on the structure of AI systems, such as the type of neural network or the algorithm being used.
Don’t Rely Solely on Claim Language: As the court emphasized, merely parroting the claim language in the specification is not enough. It’s crucial to explain the structural components in detail, particularly for AI inventions that involve complex algorithms and system architectures.
Conclusion: The Need for Clarity in AI Patents
The Federal Circuit’s decision underscores the importance of clarity and specificity in patent claims, particularly in fields like software and AI, where functional terms are commonly used. Patent applicants must ensure that functional language is supported by concrete structural details to avoid claims being deemed indefinite under § 112 ¶6. By providing comprehensive descriptions of the structure and algorithms underlying their inventions, AI patent drafters can strengthen their patent applications and reduce the risk of invalidation due to indefiniteness.
As AI technologies continue to evolve, patent law will need to adapt, and the case serves as a timely reminder that functional claims must be backed by sufficient structure to withstand legal scrutiny.
Akums Drugs & Pharmaceuticals Secures Patent for Extended-Release Doxylamine and Pyridoxine Formulation for Nausea and Vomiting in Pregnancy
In a significant breakthrough for maternal healthcare, Akums Drugs & Pharmaceuticals has been granted a patent for its extended-release combination formulation of Doxylamine and Pyridoxine, developed to manage nausea and vomiting in pregnancy (NVP). The formulation, which utilizes Akums’ proprietary “tablet-in-tablet” technology, has recently received approval from the Drug Controller General of India (DCGI).
Addressing a Widespread Issue in Pregnancy Care
NVP can severely impact a woman’s nutrition, daily activities, and overall well-being, creating a need for effective treatments that address both the short-term and long-term needs of expectant mothers.
Akums’ innovative formulation provides an effective solution to this problem by combining the benefits of immediate and extended drug release in a single tablet. This novel combination is designed to offer prolonged symptom relief and reduce the frequency of dosing, improving patient adherence to the treatment regimen.
Dual-Action Mechanism for Improved Convenience
The tablet-in-tablet technology developed by Akums is a significant advancement in drug delivery. The formulation consists of two layers: an outer layer that provides a rapid onset of action to quickly alleviate the symptoms of nausea, and an inner core that ensures a longer therapeutic effect. This dual-action mechanism aims to enhance the convenience of treatment by reducing the need for frequent dosing and improving overall symptom management.
The company believes that this formulation will offer better symptom control for expectant mothers, allowing them to manage NVP more effectively and comfortably throughout their pregnancy.
Key Approvals and Regulatory Considerations
The DCGI approval marks a pivotal moment in Akums’ journey to provide a solution for a widespread condition that affects many pregnant women. The formulation has already undergone a bioequivalence study, and while the specific number of subjects in the study remains confidential due to regulatory norms, Akums confirmed that the data submitted was sufficient for obtaining the DCGI’s approval.
The company emphasizes that the approval of this extended-release formulation provides a new treatment option for expectant mothers, addressing a significant gap in pregnancy care by offering long-lasting control of nausea and vomiting. Akums has designed the formulation with a focus on safety, efficacy, and patient adherence, ensuring that it can be a trusted part of pregnancy care routines.
The launch of this new formulation underscores Akums’ commitment to innovative drug delivery technologies and their ongoing efforts to address significant unmet needs in the pharmaceutical market. The company is known for its robust contract development and manufacturing organization (CDMO) services, and this latest development adds to its growing portfolio of drug delivery innovations.
Akums’ Expansive Operations and Product Portfolio
Akums operates with a large-scale infrastructure that includes 12 manufacturing units, four R&D centers, and over 16,000 employees. The company reports having successfully commercialized over 4,100 formulations and has more than 220 products under development across various therapeutic categories.
The approval of the Doxylamine and Pyridoxine combination formulation is part of Akums’ broader strategic initiative to enhance its presence in both domestic and export pharmaceutical markets. The company’s growing product pipeline spans a wide range of dosage forms and therapeutic areas, reflecting its ability to innovate in diverse segments of the pharmaceutical industry.
A Key Step in Pregnancy Care
This development is a step forward in addressing the challenges faced by pregnant women suffering from NVP. By offering an extended-release formulation, Akums has created a treatment that not only provides effective symptom control but also improves the convenience and adherence to medication, which is often a challenge for expectant mothers managing NVP.
The formulation is poised to meet the growing demand for more accessible and effective healthcare options for pregnant women. Akums’ focus on patient-centric innovation positions the company as a key player in improving maternal health outcomes, particularly in regions where access to modern treatments remains a challenge.
Looking Ahead
With the DCGI’s approval, Akums is now poised to roll out this extended-release Doxylamine and Pyridoxine formulation to a wide market, benefiting pregnant women across India and potentially beyond. As the company continues to expand its research and development efforts, it is likely to remain at the forefront of pharmaceutical innovation, developing new treatments that meet the evolving needs of patients in both domestic and international markets.
In summary, Akums’ patented formulation for nausea and vomiting in pregnancy represents a significant achievement in the realm of maternal health. By leveraging its proprietary drug delivery technology and addressing a critical gap in pregnancy care, Akums is setting new standards for how pharmaceutical companies can innovate to improve the quality of life for expectant mothers.
Addressing a Widespread Issue in Pregnancy Care
NVP can severely impact a woman’s nutrition, daily activities, and overall well-being, creating a need for effective treatments that address both the short-term and long-term needs of expectant mothers.
Akums’ innovative formulation provides an effective solution to this problem by combining the benefits of immediate and extended drug release in a single tablet. This novel combination is designed to offer prolonged symptom relief and reduce the frequency of dosing, improving patient adherence to the treatment regimen.
Dual-Action Mechanism for Improved Convenience
The tablet-in-tablet technology developed by Akums is a significant advancement in drug delivery. The formulation consists of two layers: an outer layer that provides a rapid onset of action to quickly alleviate the symptoms of nausea, and an inner core that ensures a longer therapeutic effect. This dual-action mechanism aims to enhance the convenience of treatment by reducing the need for frequent dosing and improving overall symptom management.
The company believes that this formulation will offer better symptom control for expectant mothers, allowing them to manage NVP more effectively and comfortably throughout their pregnancy.
Key Approvals and Regulatory Considerations
The DCGI approval marks a pivotal moment in Akums’ journey to provide a solution for a widespread condition that affects many pregnant women. The formulation has already undergone a bioequivalence study, and while the specific number of subjects in the study remains confidential due to regulatory norms, Akums confirmed that the data submitted was sufficient for obtaining the DCGI’s approval.
The company emphasizes that the approval of this extended-release formulation provides a new treatment option for expectant mothers, addressing a significant gap in pregnancy care by offering long-lasting control of nausea and vomiting. Akums has designed the formulation with a focus on safety, efficacy, and patient adherence, ensuring that it can be a trusted part of pregnancy care routines.
The launch of this new formulation underscores Akums’ commitment to innovative drug delivery technologies and their ongoing efforts to address significant unmet needs in the pharmaceutical market. The company is known for its robust contract development and manufacturing organization (CDMO) services, and this latest development adds to its growing portfolio of drug delivery innovations.
Akums’ Expansive Operations and Product Portfolio
Akums operates with a large-scale infrastructure that includes 12 manufacturing units, four R&D centers, and over 16,000 employees. The company reports having successfully commercialized over 4,100 formulations and has more than 220 products under development across various therapeutic categories.
The approval of the Doxylamine and Pyridoxine combination formulation is part of Akums’ broader strategic initiative to enhance its presence in both domestic and export pharmaceutical markets. The company’s growing product pipeline spans a wide range of dosage forms and therapeutic areas, reflecting its ability to innovate in diverse segments of the pharmaceutical industry.
A Key Step in Pregnancy Care
This development is a step forward in addressing the challenges faced by pregnant women suffering from NVP. By offering an extended-release formulation, Akums has created a treatment that not only provides effective symptom control but also improves the convenience and adherence to medication, which is often a challenge for expectant mothers managing NVP.
The formulation is poised to meet the growing demand for more accessible and effective healthcare options for pregnant women. Akums’ focus on patient-centric innovation positions the company as a key player in improving maternal health outcomes, particularly in regions where access to modern treatments remains a challenge.
Looking Ahead
With the DCGI’s approval, Akums is now poised to roll out this extended-release Doxylamine and Pyridoxine formulation to a wide market, benefiting pregnant women across India and potentially beyond. As the company continues to expand its research and development efforts, it is likely to remain at the forefront of pharmaceutical innovation, developing new treatments that meet the evolving needs of patients in both domestic and international markets.
In summary, Akums’ patented formulation for nausea and vomiting in pregnancy represents a significant achievement in the realm of maternal health. By leveraging its proprietary drug delivery technology and addressing a critical gap in pregnancy care, Akums is setting new standards for how pharmaceutical companies can innovate to improve the quality of life for expectant mothers.
Patent Applicants Face Tighter Deadlines: What the New USPTO Rule Means for Continuation and Divisional Applications
Starting May 13, 2025, patent applicants will experience a significant change in the timeline for filing continuation and divisional applications with the U.S. Patent and Trademark Office (USPTO). Under the new rule, the window between paying the issue fee and a patent officially issuing will shrink dramatically—from about three weeks to just one week.
For those familiar with the process, this may feel like a significant shift. Previously, applicants had a comfortable amount of time to make key decisions regarding the filing of continuation or divisional applications after paying the issue fee. This period, although not extensive, offered ample opportunity to consider further filings and get the necessary paperwork in order. Now, with the new timeline, applicants will have to act quickly or risk missing the opportunity to file these crucial applications before the parent patent officially issues.
A Major Change for Continuation and Divisional Filings
For those in the patent world, continuation and divisional applications are powerful tools used to refine, expand, or protect different aspects of an invention disclosed in the original patent application. These tools allow applicants to pursue additional claims or protect additional inventions within the same family of patents.
This might happen if an applicant wants broader protection or if new claims emerge that were not included in the original application. A continuation application essentially gives the applicant another opportunity to further develop the patent without starting the process from scratch.
Divisionals, on the other hand, are filed when the USPTO requests the applicant to divide the original application into separate filings because the application covers more than one invention. This is typically seen in cases where the original application is too broad or contains more than one distinct invention.
The critical detail here is that both continuation and divisional applications must be filed before the parent patent is granted. Once the patent issues, the opportunity to file such applications is largely closed, and reopening prosecution after issuance can be costly and difficult.
The New Deadline: A Week to Act
Historically, applicants had about three weeks, sometimes longer, to file continuation or divisional applications after paying the issue fee. This gave them time to review their options, consult with colleagues or patent attorneys, and finalize their strategy before the patent officially issued.
However, with the new rule coming into effect on May 13, 2025, applicants will have only one week between paying the issue fee and the patent issuing. This means the timeline for making decisions has been drastically compressed. The issue fee, which is typically paid after receiving a Notice of Allowance from the USPTO, serves as an indication that the patent is about to be granted. With the tighter timeline, applicants must be ready to act quickly to file continuation or divisional applications—or risk missing the opportunity altogether.
For patent professionals who file these types of applications regularly, this change represents a considerable shift in workflow. The new rule is likely to require better planning, quicker decision-making, and perhaps even a shift in internal procedures to ensure applications are filed on time.
Best Practices for Navigating the Change
While the new rule presents challenges, there are several best practices that applicants can adopt to ensure they stay ahead of the game:
File Before Paying the Issue Fee
This gives ample time to review the strategy and decide on any additional filings. Filing before paying the issue fee ensures that applicants can secure their desired protection without the stress of a shortened timeline.
Incorporate Continuation and Divisional Discussions into the Review Process
Patent applicants should include discussions of continuation and divisional strategies as part of their regular Notice of Allowance review. This can involve consulting with patent attorneys, revisiting claims, and carefully evaluating whether additional applications are necessary.
Set Internal Deadlines
This gives teams time to deliberate and take a more measured approach to filings, without the added pressure of an approaching deadline.
Treat the Issue Fee as a Warning Signal
The issue fee payment should be viewed as a signal to take immediate action, not as a last-minute task. Instead of waiting until the last moment, applicants should be proactive and take time to file any necessary applications well ahead of the fee payment deadline. Procrastination can lead to missed opportunities.
Why the Change Matters
The USPTO’s decision to tighten this filing window is likely a response to the growing complexity of the patent process and the increasing speed at which innovation is occurring.
For applicants, however, this presents a new set of challenges. The need for quick decision-making and a more nimble approach to patent strategy has never been more important. Companies will need to ensure their patent portfolios are managed with greater efficiency and foresight. In particular, patent attorneys and in-house counsel will need to be highly organized to ensure that crucial filings are made within the shortened timeline.
The Bottom Line: Speed and Preparation Are Key
The new rule that takes effect on May 13, 2025, is a significant change that will impact the way patent applicants file continuation and divisional applications. With only one week between paying the issue fee and the patent issuing, applicants must be prepared to act quickly to protect additional claims or inventions.
The smartest strategy is to file continuation and divisional applications before paying the issue fee, giving applicants more time to review and finalize their filing strategy. By setting internal deadlines, planning ahead, and treating the issue fee payment as a cue to take immediate action, patent applicants can ensure they are not caught off guard by the new, shorter timeline.
In the world of patent law, timing is everything—and starting May 2025, those who act early will be best positioned to navigate the new filing requirements.
For those familiar with the process, this may feel like a significant shift. Previously, applicants had a comfortable amount of time to make key decisions regarding the filing of continuation or divisional applications after paying the issue fee. This period, although not extensive, offered ample opportunity to consider further filings and get the necessary paperwork in order. Now, with the new timeline, applicants will have to act quickly or risk missing the opportunity to file these crucial applications before the parent patent officially issues.
A Major Change for Continuation and Divisional Filings
For those in the patent world, continuation and divisional applications are powerful tools used to refine, expand, or protect different aspects of an invention disclosed in the original patent application. These tools allow applicants to pursue additional claims or protect additional inventions within the same family of patents.
This might happen if an applicant wants broader protection or if new claims emerge that were not included in the original application. A continuation application essentially gives the applicant another opportunity to further develop the patent without starting the process from scratch.
Divisionals, on the other hand, are filed when the USPTO requests the applicant to divide the original application into separate filings because the application covers more than one invention. This is typically seen in cases where the original application is too broad or contains more than one distinct invention.
The critical detail here is that both continuation and divisional applications must be filed before the parent patent is granted. Once the patent issues, the opportunity to file such applications is largely closed, and reopening prosecution after issuance can be costly and difficult.
The New Deadline: A Week to Act
Historically, applicants had about three weeks, sometimes longer, to file continuation or divisional applications after paying the issue fee. This gave them time to review their options, consult with colleagues or patent attorneys, and finalize their strategy before the patent officially issued.
However, with the new rule coming into effect on May 13, 2025, applicants will have only one week between paying the issue fee and the patent issuing. This means the timeline for making decisions has been drastically compressed. The issue fee, which is typically paid after receiving a Notice of Allowance from the USPTO, serves as an indication that the patent is about to be granted. With the tighter timeline, applicants must be ready to act quickly to file continuation or divisional applications—or risk missing the opportunity altogether.
For patent professionals who file these types of applications regularly, this change represents a considerable shift in workflow. The new rule is likely to require better planning, quicker decision-making, and perhaps even a shift in internal procedures to ensure applications are filed on time.
Best Practices for Navigating the Change
While the new rule presents challenges, there are several best practices that applicants can adopt to ensure they stay ahead of the game:
File Before Paying the Issue Fee
This gives ample time to review the strategy and decide on any additional filings. Filing before paying the issue fee ensures that applicants can secure their desired protection without the stress of a shortened timeline.
Incorporate Continuation and Divisional Discussions into the Review Process
Patent applicants should include discussions of continuation and divisional strategies as part of their regular Notice of Allowance review. This can involve consulting with patent attorneys, revisiting claims, and carefully evaluating whether additional applications are necessary.
Set Internal Deadlines
This gives teams time to deliberate and take a more measured approach to filings, without the added pressure of an approaching deadline.
Treat the Issue Fee as a Warning Signal
The issue fee payment should be viewed as a signal to take immediate action, not as a last-minute task. Instead of waiting until the last moment, applicants should be proactive and take time to file any necessary applications well ahead of the fee payment deadline. Procrastination can lead to missed opportunities.
Why the Change Matters
The USPTO’s decision to tighten this filing window is likely a response to the growing complexity of the patent process and the increasing speed at which innovation is occurring.
For applicants, however, this presents a new set of challenges. The need for quick decision-making and a more nimble approach to patent strategy has never been more important. Companies will need to ensure their patent portfolios are managed with greater efficiency and foresight. In particular, patent attorneys and in-house counsel will need to be highly organized to ensure that crucial filings are made within the shortened timeline.
The Bottom Line: Speed and Preparation Are Key
The new rule that takes effect on May 13, 2025, is a significant change that will impact the way patent applicants file continuation and divisional applications. With only one week between paying the issue fee and the patent issuing, applicants must be prepared to act quickly to protect additional claims or inventions.
The smartest strategy is to file continuation and divisional applications before paying the issue fee, giving applicants more time to review and finalize their filing strategy. By setting internal deadlines, planning ahead, and treating the issue fee payment as a cue to take immediate action, patent applicants can ensure they are not caught off guard by the new, shorter timeline.
In the world of patent law, timing is everything—and starting May 2025, those who act early will be best positioned to navigate the new filing requirements.
Indian Patent Granted for Cutting-Edge Drought Monitoring System Using AI, IoT, and Geospatial Technology
In a significant step forward for drought preparedness and management, the Indian Patent Office has granted a patent for an advanced system that utilizes AI, Internet of Things (IoT), and geospatial technologies to monitor and assess drought conditions in real time.
Designed to address the pressing need for accurate and timely drought data—particularly in vulnerable regions like Marathwada, which frequently faces water shortages—the system offers a modern alternative to outdated assessment methods.
“Conventional techniques such as Annewari and Paisewari, while historically relevant, are not equipped to deliver the precision and speed required for effective drought response today,” said Prof. Kale. “These methods often delay estimates until months after crop damage has occurred—December for Kharif and March for Rabi—hampering timely relief efforts.”
The patented technology was the result of collaborative research led by Gaikwad with critical contributions from Dr. Amol Vibhute, Dr. Rajesh Dhumal, and Dr. Rupali Surase. Their innovation integrates satellite-based remote sensing, mobile-based field data collection, and IoT-enabled sensor networks to deliver highly accurate and localized drought assessments.
A pilot implementation of the system was carried out in the Vaijapur tehsil of Chhatrapati Sambhajinagar district, a region known for recurrent droughts. According to Gaikwad, the new system demonstrated strong potential to transform the way droughts are tracked and responded to.
“This solution provides real-time, location-specific insights that can help authorities and farmers take timely preventive measures, ultimately minimizing the agricultural and socio-economic impact of droughts,” Gaikwad explained.
Prof. Kale added that the system is not only scalable but also adaptable for use in other drought-prone areas across India. The team believes that this technology could play a vital role in strengthening the country’s resilience to climate-induced challenges in agriculture.
Designed to address the pressing need for accurate and timely drought data—particularly in vulnerable regions like Marathwada, which frequently faces water shortages—the system offers a modern alternative to outdated assessment methods.
“Conventional techniques such as Annewari and Paisewari, while historically relevant, are not equipped to deliver the precision and speed required for effective drought response today,” said Prof. Kale. “These methods often delay estimates until months after crop damage has occurred—December for Kharif and March for Rabi—hampering timely relief efforts.”
The patented technology was the result of collaborative research led by Gaikwad with critical contributions from Dr. Amol Vibhute, Dr. Rajesh Dhumal, and Dr. Rupali Surase. Their innovation integrates satellite-based remote sensing, mobile-based field data collection, and IoT-enabled sensor networks to deliver highly accurate and localized drought assessments.
A pilot implementation of the system was carried out in the Vaijapur tehsil of Chhatrapati Sambhajinagar district, a region known for recurrent droughts. According to Gaikwad, the new system demonstrated strong potential to transform the way droughts are tracked and responded to.
“This solution provides real-time, location-specific insights that can help authorities and farmers take timely preventive measures, ultimately minimizing the agricultural and socio-economic impact of droughts,” Gaikwad explained.
Prof. Kale added that the system is not only scalable but also adaptable for use in other drought-prone areas across India. The team believes that this technology could play a vital role in strengthening the country’s resilience to climate-induced challenges in agriculture.
Patent Dispute Erupts Over Scavenger Robots: Kerala’s Genrobotics Files Lawsuit Against IIT Madras Startup
A legal battle has broken out in the field of sanitation technology as Genrobotics, a Kerala-based robotics company known for its sewer-cleaning robot ‘Bandicoot’, has taken legal action against a startup incubated at IIT Madras. The dispute centers on alleged patent infringement involving robotic systems designed to eliminate manual scavenging.
The company argues that its patented design and mechanism have been replicated without authorization, potentially undermining years of research and development.
The case highlights growing tensions in India’s deep tech and robotics sectors, where startups and research institutions are increasingly innovating but also entering complex territory involving patents and proprietary technologies.
According to Genrobotics, its invention was created specifically to address the inhumane practice of manual scavenging, offering a safer and more dignified alternative through automation. The company has received widespread recognition and government support for deploying its technology across multiple states.
The IIT Madras startup, whose identity has not been officially disclosed in legal documents, reportedly launched a robotic solution with functions and features that Genrobotics claims are too similar to be coincidental. Genrobotics has approached the courts seeking an injunction against the manufacture, sale, and promotion of the allegedly infringing product.
Industry observers note that this case could set a precedent for how intellectual property rights are enforced in India’s emerging robotics industry. It also raises broader questions about the balance between innovation, open research, and patent protection, particularly in sectors aimed at solving critical social issues.
Neither side has made a detailed public statement yet, but the case is expected to draw attention as it unfolds, especially given the increasing focus on technology-driven solutions in public sanitation.
The company argues that its patented design and mechanism have been replicated without authorization, potentially undermining years of research and development.
The case highlights growing tensions in India’s deep tech and robotics sectors, where startups and research institutions are increasingly innovating but also entering complex territory involving patents and proprietary technologies.
According to Genrobotics, its invention was created specifically to address the inhumane practice of manual scavenging, offering a safer and more dignified alternative through automation. The company has received widespread recognition and government support for deploying its technology across multiple states.
The IIT Madras startup, whose identity has not been officially disclosed in legal documents, reportedly launched a robotic solution with functions and features that Genrobotics claims are too similar to be coincidental. Genrobotics has approached the courts seeking an injunction against the manufacture, sale, and promotion of the allegedly infringing product.
Industry observers note that this case could set a precedent for how intellectual property rights are enforced in India’s emerging robotics industry. It also raises broader questions about the balance between innovation, open research, and patent protection, particularly in sectors aimed at solving critical social issues.
Neither side has made a detailed public statement yet, but the case is expected to draw attention as it unfolds, especially given the increasing focus on technology-driven solutions in public sanitation.